Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 10Not yet recruiting 3Completed 3Enrolling by invitation 2Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Osteosarcoma 1Neoplasms by Site 1Mouth Neoplasms 1Lung Neoplasms 1Lung Diseases 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Neoplasms 1

Interventions

Cisplatin 45Radiotherapy 32Fluorouracil 27Paclitaxel 26Irinotecan 17Docetaxel 16Oxaliplatin 11Carboplatin 10pembrolizumab 9Cetuximab 8tislelizumab 7Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Radiation 6Leucovorin 6sintilimab 5Nivolumab 5Immunohistochemistry 5Chemotherapy, Adjuvant 5Capecitabine 5nedaplatin 3durvalumab 3camrelizumab 3S 1 (combination) 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Esophageal Squamous Cell Carcinoma × camrelizumab × Clear all
NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Anhui Provincial Hospital

Phase 2 Completed
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT04225364 2021-02-02

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Guangzhou Institute of Respiratory Disease

Phase 2 Completed
56 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Hangzhou Cancer Hospital

Phase 2 Completed
25 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡